Adagene Inc. (ADAG)
ADAG Stock Price Chart
Explore Adagene Inc. interactive price chart. Choose custom timeframes to analyze ADAG price movements and trends.
ADAG Company Profile
Discover essential business fundamentals and corporate details for Adagene Inc. (ADAG) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 Feb 2021
Employees
138.00
Website
https://www.adagene.comCEO
Peter Luo
Description
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
ADAG Financial Timeline
Browse a chronological timeline of Adagene Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.22, while revenue estimate is $17.50m.
Earnings released on 1 Apr 2026
EPS came in at -$0.07 surpassing the estimated -$0.28 by +75.00%, while revenue for the quarter reached $7.69m , missing expectations by -56.08%.
Earnings released on 23 Mar 2026
Earnings released on 24 Mar 2025
EPS came in at -$0.55 falling short of the estimated -$0.33 by -67.69%, while revenue for the quarter reached $103.20k .
Earnings released on 25 Jul 2024
EPS came in at -$0.19 surpassing the estimated -$0.41 by +53.03%.
Earnings released on 31 Mar 2024
EPS came in at -$0.19 .
Earnings released on 29 Mar 2024
EPS came in at -$0.17 surpassing the estimated -$0.42 by +59.76%, while revenue for the quarter reached $407.87k .
Earnings released on 30 Sept 2023
EPS came in at -$0.17 , while revenue for the quarter reached $407.87k .
Earnings released on 31 Aug 2023
EPS came in at -$0.05 surpassing the estimated -$0.38 by +87.62%, while revenue for the quarter reached $8.65m .
Earnings released on 31 Mar 2023
EPS came in at -$0.05 , while revenue for the quarter reached $8.65m .
Earnings released on 28 Mar 2023
EPS came in at -$1.55 falling short of the estimated -$0.40 by -287.50%, while revenue for the quarter reached $2.68m , missing expectations by -72.99%.
Earnings released on 30 Sept 2022
EPS came in at -$0.38 , while revenue for the quarter reached $2.68m .
Earnings released on 30 Aug 2022
EPS came in at -$1.09 falling short of the estimated -$0.65 by -68.01%, while revenue for the quarter reached $3.92m , missing expectations by -77.58%.
Earnings released on 30 Sept 2021
EPS came in at -$0.41 , while revenue for the quarter reached $4.41m .
Earnings released on 26 Aug 2021
EPS came in at -$1.02 falling short of the estimated -$0.39 by -161.89%, while revenue for the quarter reached $1.36m .
ADAG Stock Performance
Access detailed ADAG performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
